Medical Cannabis Side Effects: What the Clinical Evidence Actually Shows

Most patient-facing websites about medical cannabis follow a familiar template: lead with the benefits, mention side effects briefly, and move on. This article takes a different approach. If you are considering a medical cannabis prescription in the UK, or have already been prescribed it, you deserve an accurate, evidence-based account of what the clinical literature actually shows — the good, the uncertain and the genuinely concerning.

Medical cannabis has been legally prescribable in England, Scotland, Wales and Northern Ireland since November 2018. Since then, tens of thousands of patients have received prescriptions, primarily through private specialist clinics. The medicines involved range from CBD-dominant oils with negligible THC content to high-potency inhaled flower products containing 20-25% THC. These are not interchangeable, and neither are their side effect profiles.

This guide draws on guidance from the Medicines and Healthcare products Regulatory Agency (MHRA), NICE Technology Appraisals, and the World Health Organisation Expert Committee on Drug Dependence (ECDD). Where evidence is robust, we say so. Where it is limited, we say that too.

This article does not constitute medical advice. Always consult your prescribing clinician before making any changes to your treatment. For personalised guidance, see our Find a Doctor directory or read our comprehensive UK patient guide.

Common Short-Term Side Effects of Medical Cannabis

The short-term adverse effects of medical cannabis are well-characterised in clinical literature. They are predominantly dose-dependent, meaning they are more likely to occur at higher doses and can often be managed through careful titration — the process of starting at a low dose and increasing gradually under clinical supervision.

The most frequently reported short-term side effects across systematic reviews include:

• Dizziness and light-headedness — reported in up to 30% of patients in some trials, particularly with inhaled or sublingually administered THC products. Often transient, occurring shortly after administration.
• Dry mouth (xerostomia) — caused by cannabinoid receptor activity in salivary glands. Common across both THC and CBD products but rarely clinically significant.
• Fatigue and sedation — particularly relevant for daytime functioning and driving. More pronounced with indica-dominant, high-THC products.
• Nausea — paradoxically, while medical cannabis is prescribed to treat chemotherapy-induced nausea, it can itself cause nausea in some patients, particularly at the outset of treatment.
• Increased heart rate (tachycardia) — THC activates cannabinoid receptors that modulate cardiovascular function. Clinically significant in patients with pre-existing cardiac conditions.
• Disorientation and impaired coordination — dose-dependent, more pronounced in cannabis-naive patients and with rapid-onset delivery methods.
• Appetite changes — typically increased appetite with THC; reduced or unchanged with CBD. Therapeutically useful in some contexts, unwanted in others.

The majority of these effects are transient and diminish with continued use as the patient develops pharmacological tolerance. However, tolerance itself carries its own longer-term implications, discussed in the section on dependency below.

THC vs CBD: Very Different Risk Profiles

One of the most significant sources of confusion in public discourse about medical cannabis is the conflation of THC and CBD. They are both cannabinoids, both found in the cannabis plant, and both present in many prescribed products — but their pharmacological profiles and risk characteristics are substantially different.

Tetrahydrocannabinol (THC) is the primary psychoactive constituent of cannabis. It binds directly to CB1 receptors in the brain, producing the characteristic intoxication associated with recreational cannabis use. The side effects most associated with medical cannabis — psychosis risk, cognitive impairment, dependency, and driving impairment — are predominantly attributable to THC.

Cannabidiol (CBD) has a markedly different receptor profile. It does not produce intoxication, has a weak affinity for CB1 receptors, and acts through multiple other mechanisms including 5-HT1A serotonin receptors and TRPV1 channels. The WHO ECDD has concluded that CBD exhibits no potential for abuse and no public health risks in its pure state. The most clinically significant adverse effects associated with CBD — primarily elevated liver enzymes and drug interactions — are observed mainly at the high doses used in pharmaceutical-grade preparations such as Epidyolex.

Patients prescribed a CBD-dominant product with less than 1% THC face a genuinely different risk landscape than those prescribed a 22% THC flower product. Any honest discussion of medical cannabis side effects must make this distinction clearly.

Side Effect	Frequency (THC-dominant)	Frequency (CBD-dominant)
Dizziness / light-headedness	Very Common (>10%)	Uncommon (<1%)
Dry mouth	Very Common (>10%)	Common (1-10%)
Sedation / fatigue	Very Common (>10%)	Common (1-10%)
Nausea	Common (1-10%)	Common (1-10%)
Tachycardia	Common (1-10%)	Rare (<0.1%)
Anxiety / paranoia	Common (1-10%)	Rare (<0.1%)
Cognitive impairment	Common (1-10%)	Very Rare
Psychotic symptoms	Uncommon (0.1-1%)	Not established
Elevated liver enzymes	Rare	Common at high doses
Drug interactions (CYP450)	Moderate risk	Higher risk
Dependency / withdrawal	Common (long-term)	Not established

Mental Health Risks: What the Evidence Says

The relationship between cannabis and mental health is one of the most scrutinised — and most contested — areas in the entire pharmacological literature. The evidence warrants a careful, nuanced reading rather than either dismissal or alarm.

Psychosis risk. The association between high-potency cannabis use and psychosis is among the most robust findings in psychiatric epidemiology. A landmark 2019 study published in The Lancet Psychiatry found that daily use of high-potency cannabis (defined as more than 10% THC) was associated with a five-fold increase in the odds of psychosis compared with non-users. THC activates dopamine release in mesolimbic pathways in a manner that can precipitate or exacerbate psychotic symptoms in vulnerable individuals.

The critical question for medical use is whether controlled, lower-dose THC administration in a clinical setting carries the same risk as high-volume recreational use. The honest answer is that we do not yet have adequate long-term clinical trial data to answer this with certainty. NICE Technology Appraisals on cannabis-based medicinal products acknowledge this evidence gap explicitly. What the clinical consensus does support is that patients with a personal or family history of psychosis, schizophrenia, or bipolar disorder should not be prescribed THC-containing products — and this is reflected in standard clinical exclusion criteria across the UK.

Anxiety exacerbation. THC has a biphasic relationship with anxiety: at low doses it may reduce anxiety; at higher doses or in susceptible individuals it reliably provokes it. This is particularly relevant because anxiety disorders are one of the most common conditions for which patients in the UK seek medical cannabis prescriptions. The evidence base for THC in treating anxiety is considerably weaker than for conditions such as chronic pain or chemotherapy-induced nausea. Patients with anxiety disorders prescribed THC-containing products should be monitored closely for symptom exacerbation, particularly in the titration phase.

Depression. The relationship is similarly complex. Observational data suggests heavy cannabis users have elevated rates of depression, but causality is difficult to establish — people with depression may self-medicate with cannabis rather than cannabis causing depression. Clinical trials specifically targeting depression with medical cannabis are limited. Patients with active depression should discuss the risk-benefit balance carefully with their prescriber.

Cognitive Effects and Driving: The UK Legal Position

THC impairs a cluster of cognitive functions directly relevant to driving safety: reaction time, divided attention, short-term memory consolidation, and spatial processing. The impairment is dose-dependent and, unlike alcohol, does not correlate straightforwardly with blood or breath levels — meaning there is no reliable equivalent of a breathalyser test for cannabis intoxication.

The UK legal position is unambiguous. Under the Drug Driving (Specified Limits) (England and Wales) Regulations 2014, driving with a blood THC concentration above 2 micrograms per litre is a criminal offence, regardless of whether the cannabis was prescribed. Scotland and Northern Ireland have equivalent provisions. The legislation includes a statutory medical defence, but this defence is narrow: it applies only where the patient was driving in accordance with medical advice and the presence of the controlled drug did not impair their driving. The burden of demonstrating this in court is substantial.

In practical terms, patients prescribed THC-containing medical cannabis products should not drive immediately after administration, and should be aware that residual impairment and measurable blood levels can persist for considerably longer than the subjective effects. Patients using high-potency products daily may have detectable THC levels at all times. This is a genuine, significant implication of a THC prescription that prescribers are obligated to discuss before treatment commences.

CBD-only products do not contain THC and do not impair driving. For more detail on prescribing pathways, see our UK dosing guide.

Long-Term Use: Dependency, Tolerance and Withdrawal

Cannabis use disorder — the clinical term for problematic dependency on cannabis — is a recognised psychiatric diagnosis. The WHO estimates that approximately 9% of people who use cannabis will develop dependency. This figure rises substantially among those who begin use in adolescence or who use daily, high-potency products over extended periods.

For medical cannabis patients, particularly those prescribed THC-containing products for chronic conditions, dependency is a clinically relevant consideration. As patients develop tolerance — a reduction in effect at a given dose — they may require progressively higher doses to achieve the same therapeutic benefit. This tolerance-escalation dynamic is familiar from other analgesics, including opioids, and carries similar risks: the therapeutic window narrows, side effects become more pronounced, and discontinuation becomes more difficult.

Cannabis Withdrawal Syndrome is recognised in DSM-5 and ICD-11. Symptoms typically emerge 24-72 hours after cessation in daily users and include irritability and aggression, anxiety, sleep disturbance, decreased appetite, restlessness, depression, and physical symptoms including sweating, tremors and abdominal pain. The syndrome is rarely medically dangerous but can be clinically significant and may deter patients from attempting to reduce their dose. UK clinical guidelines do not yet include standardised protocols for managing cannabis withdrawal in medical patients. Patients who are concerned about dependency should raise this explicitly with their prescribing clinician rather than discontinuing abruptly.

Side Effects by Condition and Patient Profile

Side effect risk is not uniform across patients. Age, sex, body weight, genetic variants in cannabinoid metabolism, prior cannabis exposure, concurrent medications, and the specific condition being treated all modulate how an individual will respond to a given medical cannabis product.

Chronic pain patients — typically the largest group in UK medical cannabis practice — often report good tolerability, particularly with balanced THC:CBD products. However, the literature supporting long-term use for chronic pain relies heavily on observational data; randomised controlled trial evidence remains limited, a point NICE has made explicitly in its appraisals.

Epilepsy patients prescribed Epidyolex (pharmaceutical-grade CBD) have the most robust clinical trial data of any cannabis-based medicine licensed in the UK. The most clinically significant side effects in this population are elevated liver enzymes and drug interactions — particularly with clobazam, valproate and other antiepileptic drugs. Regular liver function monitoring is required.

Cancer patients using THC-containing products for nausea and appetite stimulation generally tolerate short-term use well, but are often on complex medication regimens. Drug-drug interactions via the CYP450 enzyme system — where both THC and CBD can inhibit metabolism of co-administered drugs — require careful clinical assessment.

Older patients are more susceptible to falls, cognitive side effects and cardiovascular effects from THC. Lower starting doses and slower titration are particularly important in this demographic. The interaction with anticoagulants such as warfarin is well-documented and requires INR monitoring.

Patients with anxiety or PTSD represent a high-risk group for THC-associated psychiatric adverse effects. The evidence base for medical cannabis in PTSD is mixed, and the potential for THC to exacerbate anxiety means that careful patient selection and close monitoring are essential.

Managing Side Effects: Clinical Monitoring in UK Practice

Responsible medical cannabis prescribing in the UK is characterised by structured monitoring. The following clinical practices are considered standard in compliant specialist clinics:

• Baseline assessment — mental health history, cardiovascular history, current medications, and prior cannabis exposure documented before any prescription is issued.
• Low and slow titration — starting at the lowest effective dose and increasing incrementally substantially reduces the incidence and severity of adverse effects.
• Regular follow-up — monthly or quarterly review appointments to assess efficacy, side effects, and any changes in concurrent medications or health status.
• Standardised outcome measures — tools such as the Patient Global Impression of Change (PGIC) and validated pain or quality-of-life scales to monitor treatment response objectively.
• Liver function tests — required for patients on CBD preparations, particularly Epidyolex or high-dose CBD oils.
• Drug interaction review — formal assessment of any co-administered medications metabolised via CYP3A4 or CYP2C9 pathways, where THC and CBD can cause clinically significant interactions.
• Driving advice documentation — clinicians are required to advise patients about the legal implications of driving while prescribed THC-containing products.

Our For Clinicians section provides further detail on UK clinical standards for prescribers.

When Medical Cannabis Is Not Appropriate

Medical cannabis — particularly THC-containing products — is contraindicated or requires extreme caution in the following circumstances. This list is not exhaustive; clinical assessment will always be more specific to individual circumstances.

• Personal or family history of psychosis or schizophrenia — THC-containing products should not be prescribed. This is a standard exclusion criterion across UK specialist clinics.
• Pregnancy and breastfeeding — cannabinoids cross the placental barrier and are present in breast milk. No medical cannabis product is approved for use in pregnancy in the UK. Evidence of harm to foetal development from THC exposure is well-established.
• Patients under 18 — with the exception of licensed preparations for specific paediatric epilepsy conditions (Epidyolex for Dravet and Lennox-Gastaut syndromes). The developing brain is substantially more susceptible to the adverse effects of THC.
• Severe hepatic impairment — both THC and CBD are extensively metabolised in the liver. Dose adjustment or avoidance is required in patients with significant liver disease.
• Recent myocardial infarction or unstable cardiac arrhythmia — THC-induced tachycardia and cardiovascular effects represent a meaningful risk in this population.
• Active substance use disorder — not a blanket contraindication, but prescribing should proceed only with addiction specialist involvement and robust monitoring.
• Concurrent use of certain medications — particularly anticoagulants, antiepileptics, chemotherapy agents, and immunosuppressants, where drug interactions can be clinically significant and sometimes dangerous.

---

Medically reviewed by the Cannamedical Britannia Clinical Team, May 2026. This article is for informational purposes only and does not constitute medical advice. Always seek guidance from a qualified medical professional before starting, changing or stopping any treatment. Visit our Find a Doctor page or read our UK patient guide.

Sources: MHRA Guidance on Cannabis-based Products for Medicinal Use; NICE Technology Appraisal TA654 (Nabiximols); NICE Technology Appraisal TA614 (Cannabidiol, Epidyolex); WHO Expert Committee on Drug Dependence — Critical Review of Cannabis and Cannabis-related Substances (2019); Di Forti M et al., The Lancet Psychiatry, 2019; Hasin DS et al., JAMA Psychiatry, 2017; Drug Driving (Specified Limits) (England and Wales) Regulations 2014; DSM-5 Cannabis Withdrawal Criteria; ICD-11 Section 6C43.